Herpes labialis
Drug research and approvals for herpes labialis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1 studies of herpes labialis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 1
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Viral Infections in Healthy and Immunocompromised HostsNCT01306084 · Not reported · National Institute of Allergy and Infectious Diseases (NIAID) · starts Mar 15, 2011
Approved 7
- AcyclovirHuman herpesvirus 1 DNA polymerase inhibitor
- PenciclovirHuman herpesvirus 1 DNA polymerase inhibitor
- FamciclovirHuman herpesvirus 1 DNA polymerase inhibitor
- ValacyclovirHuman herpesvirus 1 DNA polymerase inhibitor
- Phenol
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- Camphor
Phase 2 9
- Alcohol
- Squaric acid dibutyl ester
- Glutamine
- PritelivirHelicase/primase inhibitor
- 2-hydroxypropyl-beta-cyclodextrinCholesterol sequestering agent
- Glycine
- Glycolic acid
- Isoxaflutole
- Clobetasol
How its trials ended
52 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 10 whose ending is known, 60% met their primary endpoint, 0% missed it and 40% stopped early.
- Completed, result not reported3567%
- Met its primary endpoint612%
- Status unknown510%
- Ongoing24%
- Stopped: sponsor or business decision24%
- Stopped: lack of efficacy12%
- Stopped: enrollment or feasibility12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA